Vivozon Recruiting Patients for Phase 1 Clinical Trial of Oral Drug Addiction Treatment

[Asia Economy Reporter Hyungsoo Park] Innovative drug development company Vibozone announced on the 11th that it has received approval from the Institutional Review Board (IRB) of Bundang Seoul National University Hospital, the domestic clinical trial institution for the oral drug addiction treatment VVZ-2471. The IRB is an ethical committee that reviews the ethical and scientific validity to ensure the safety of clinical trial participants.

Vibozone will officially begin recruiting patients for the Phase 1 clinical trial of the oral VVZ-2471. The trial will evaluate safety and tolerability in 82 healthy adult males.

VVZ-2471 is a new drug candidate that shows preventive and therapeutic effects against drug addiction for chronic pain, including neuropathic pain. Additional anxiolytic and antidepressant effects were confirmed through animal experiments conducted by the contract research organization (CRO) Naason Science.

A Vibozone representative said, "Drug addiction caused by opioid analgesics is a serious social problem worldwide," adding, "VVZ-2471 is expected to have greater future value as it is effective not only in pain control but also in drug addiction, anxiety, and depression symptoms."

Vibozone is a new drug development company with the non-opioid analgesic Ofirangerin (VVZ-149) as its core pipeline. Vibozone’s affiliate, Vibozone Healthcare, plans to complete patient enrollment for the domestic Phase 3 clinical trial of the Ofirangerin injection by the end of this month.

This content was produced with the assistance of AI translation services.